Xcout Intel
Adaptam Therapeutics
Adaptam Therapeutics is an oncology-focused immunotherapy company headquartered in San Sebastián, Basque Country, Spain, developing therapies that target immunosuppressive myeloid tumors.
Subscribe to see Adaptam Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Adaptam Therapeutics at a glance
Adaptam Therapeutics is a biotechnology company headquartered in Spain. Its most recent funding round, Pre-Seed, raised $3.2M in November 2025. Xcout tracks 4 named people at Adaptam Therapeutics, including Pablo Cironi (Chairman).
Adaptam Therapeutics leadership
- Pablo CironiChairman
- Asis PalazonCEO/CSO Founder
- José M MatoBoard Member
- Salvatore CappadonaBoard Member
Adaptam Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Pre-Seed | $3.2M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Adaptam Therapeutics competitors
A few of Adaptam Therapeutics's closest competitors — see the full list of competitors and alternatives →
Indapta Therapeutics, Inc. is a privately held biotechnology company founded in 2017 and headquartered in San Francisco, California. The company is focused on developing an innovative natural killer (NK) cell therapy platform primarily intended for treating myeloma and other diseases.
Avammune Therapeutics is an R&D-driven drug discovery company headquartered in Philadelphia, Pennsylvania. The company focuses on developing novel, modality-agnostic immunotherapies and cancer therapies to address high unmet medical needs in hard-to-treat solid tumors.
Oncomatryx is a Spanish biopharmaceutical company headquartered in Derio, Basque Country, Spain. The firm pioneers targeted oncology therapeutics aimed at treating metastatic solid tumors and utilizes advanced computational approaches in its drug discovery pipeline.
Adaptin Bio is a biotechnology company developing a proprietary drug delivery platform designed to enhance the transfer of therapeutics across biological barriers into the brain and other targeted tissues. Its lead technology, the Brain Bispecific T cell Engager (BRiTE) platform, manipulates the human immune system to target diseases in oncology, central nervous system disorders, autoimmune conditions, and cardiovascular markets.
OSE Immunotherapeutics is a clinical-stage biotechnology company that develops innovative immunotherapies for immune activation and regulation in immuno-oncology and immuno-inflammation. The company utilizes proprietary research platforms and a portfolio of clinical-stage assets to provide therapeutic options for patients.
ImmunOs Therapeutics AG is a biotechnology company that develops treatments for cancer and inflammatory diseases by harnessing the human immune system. The company focuses on immuno-oncology and autoimmune therapies through a dedicated drug pipeline.
Get Adaptam Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Adaptam Therapeutics in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access